Physician profile
James I Ewing
NPI 1689837601
$42,005.45
in general payments reported to CMS, 2019-2025
68 companies · $6,892 in 2025
The $6,892 reported for 2025 was more than what 77% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,145 · 2020: $10K · 2021: $6,068 · 2022: $1,702 · 2023: $3,245 · 2024: $5,495 · 2025: $6,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,335 · Food and Beverage: $6,691 · Travel and Lodging: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,335.00 |
| Food and Beverage | $6,691.29 |
| Travel and Lodging | $1,606.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $8,472.49 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $4,927.12 | 2019-2025 | Imfinzi, Enhertu |
| Incyte Corporation | $4,502.13 | 2020-2025 | Jakafi, Pemazyre, Monjuvi |
| Geron Corporation | $3,715.38 | 2025 | Imetelstat, Rytelo |
| Novartis Pharmaceuticals Corporation | $2,402.04 | 2019-2025 | |
| Exelixis INC. | $2,130.03 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $1,992.29 | 2023-2024 | Brukinsa |
| Gilead Sciences, INC. | $1,164.77 | 2019-2025 | Trodelvy |
| Beigene, LTD. | $975.00 | 2020-2021 | |
| Pfizer INC. | $925.77 | 2019-2025 | |
| Amgen INC. | $885.67 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Abbvie INC. | $882.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $853.70 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Merck Sharp & Dohme LLC | $831.16 | 2019-2025 | Keytruda, Welireg |
| Emd Serono, INC. | $714.37 | 2019-2023 | Bavencio, Tepmetko |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $477.94 | 2019-2025 | |
| Janssen Biotech, INC. | $464.19 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Glaxosmithkline, LLC. | $413.38 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Genentech USA, INC. | $398.42 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| Array Biopharma INC | $362.74 | 2021-2025 | Braftovi, Lorbrena, Mektovi |
| Astellas Pharma US INC | $287.92 | 2019-2025 | Xtandi, Padcev |
| Lilly USA, LLC | $278.80 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $261.25 | 2022-2025 | |
| Daiichi Sankyo INC. | $258.79 | 2021-2025 | Enhertu, Vanflyta, Injectafer |
| Pharmacyclics LLC, An Abbvie Company | $254.57 | 2020-2023 | Epkinly, Imbruvica |
| Seagen INC. | $243.62 | 2019-2023 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $198.36 | 2019-2025 | |
| Inari Medical, INC. | $194.01 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Servier Pharmaceuticals LLC | $188.59 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $162.93 | 2023-2024 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $161.16 | 2019-2025 | Iclusig |
| Rigel Pharmaceuticals, INC. | $159.23 | 2020-2025 | Tavalisse, Rezlidhia, Gavreto |
| Secura Bio, INC. | $129.16 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $126.96 | 2021-2025 | |
| Blueprint Medicines Corporation | $122.38 | 2020-2024 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $121.29 | 2020-2025 | Ultomiris |
| Genmab U.S., INC. | $100.31 | 2023-2024 | Epkinly, Tivdak |
| Ipsen Biopharmaceuticals, INC | $99.07 | 2021-2025 | Onivyde |
| Kyowa Kirin, INC. | $92.86 | 2021-2025 | |
| Tersera Therapeutics LLC | $82.02 | 2021-2023 | Zoladex |
| Cti Biopharma Corp. | $76.36 | 2022-2023 | Vonjo |
| Puma Biotechnology, INC. | $70.50 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.09 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $63.37 | 2019-2022 | |
| Stemline Therapeutics INC. | $51.32 | 2024 | Orserdu |
| Aveo Pharmaceuticals, INC. | $50.23 | 2022-2025 | |
| Mirati Therapeutics, INC. | $47.04 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $46.92 | 2020-2025 | Xpovio |
| Kerecis Limited | $44.57 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Springworks Therapeutics, INC. | $43.78 | 2024-2025 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $43.53 | 2019 | |
| Progenics Pharmaceuticals, INC. | $40.69 | 2023-2024 | Pylarify |
| Amag Pharmaceuticals, INC. | $39.48 | 2020-2021 | |
| Epizyme, INC. | $38.23 | 2021 | |
| Kite Pharma, INC. | $29.63 | 2025 | Yescarta |
| Sumitomo Pharma America, INC. | $25.16 | 2025 | Orgovyx |
| Sobi, INC | $22.01 | 2025 | |
| Organon LLC | $21.73 | 2022 | |
| Pharmaessentia USA Corporation | $20.96 | 2023 | Besremi |
| Janssen Pharmaceuticals, INC | $20.68 | 2019 | |
| Csl Behring | $20.17 | 2022 | |
| G1 Therapeutics, INC. | $18.13 | 2022 | |
| Morphosys, US INC. | $17.97 | 2021 | |
| Beone Medicines USA, INC. | $17.86 | 2025 | Brukinsa |
| Myovant Sciences INC. | $14.95 | 2021 | |
| Tolmar, INC. | $13.51 | 2023 | |
| Verastem, INC. | $12.72 | 2020 | |
| Foundation Medicine, INC. | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.